Combination drug for treating hyperlipidemia and its use
The pharmaceutical composition formed by combining 2',3',5'-tris-O-ethyl-N6-(3-hydroxyphenyl)adenosine with statins or fibrate drugs is treated in hyperlipidemia The effect of blood lipid regulation has been significantly improved, the problem of poor results in the prior art has been solved, and the treatment effect with longer-term effect and fewer side effects has been achieved.
Patent Information
- Application Number
- CN202011130790.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-10-21
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2040-10-21
AI Technical Summary
The prior art has problems with poor efficacy in the treatment of hyperlipidemia, especially in reducing blood LDL-C, TC and TG levels and inhibiting lipid de novo synthesis and fatty liver formation, which still needs improvement.
A pharmaceutical composition is used, comprising 2',3',5'-tris-O-acetyl-N6-(3-hydroxyphenyl)adenosine as the first active ingredient, in combination with statins or fibrate drugs As the second active ingredient, it is used to prevent and treat hyperlipidemia. The compositions may be made in different proportions and dosage forms (eg, tablets, capsules, injections, etc.) and administered by oral or other routes.
The composition shows synergistic effects in the treatment of hyperlipidemia, prolongs the treatment effect, reduces side effects, improves patient compliance, and maintains a good therapeutic effect after stopping the drug, which can more effectively reduce blood lipid levels and inhibit the formation of fatty liver.
Smart Images

Figure BDA0002735103160000021 
Figure BDA0002735103160000101 
Figure BDA0002735103160000111
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, including drugs and disease treatment, and particularly relates to a combined drug for treating hyperlipidemia or a disease associated with hyperlipidemia and its use. Background Art
[0002] Hyperlipidemia is a disease in which lipoprotein lipids in plasma are abnormally increased. It is closely related to coronary heart disease, arteriosclerosis, myocardial infarction and other diseases. Moreover, hyperlipidemia is also an important risk factor for hypertension and diabetes. Hyperlipidemia can also lead to fatty liver, cirrhosis, pancreatitis and other diseases. Therefore, it is considered very important to prevent and treat hyperlipidemia.
[0003] There are many drugs used for the treatment of hyperlipidemia. One common class of drugs is statins, which are hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and can be used as plasma cholesterol concentration lowering agents. Another common class of drugs is fibrates, which are peroxisome proliferator-activated receptor α (PPARα) agonists and can be used to lower triglyceride levels.
[0004] 2',3',5'-Tri-O-acetyl-N 6 -(3-Hydroxyphenyl)adenosine is a compound with lipid-regulating effects. Experiments have shown that it can improve dyslipidemia in experimental animals, reduce blood LDL-C, TC and TG levels, reduce abdominal fat accumulation, inhibit de novo lipid synthesis in the liver, increase liver lipid oxidation, increase lipid consumption, and inhibit the formation of fatty liver.
[0005] There remains a continuing need in the art for drugs with improved efficacy for the treatment of hyperlipidemia. Summary of the invention
[0006] The first aspect of the present application relates to a pharmaceutical composition or a kit for preventing and / or treating hyperlipidemia or a condition associated with hyperlipidemia, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as a first active ingredient, and a statin or a fibrate as a second active ingredient.
[0007]
[0008] The chemical name of the term "compound of formula (I)" used herein is 2',3',5'-tri-O-acetyl-N 6 -(3-hydroxyphenyl)adenosine. In the context of this application, "2',3',5'-tri-O-acetyl-N 6 -(3-hydroxyphenyl)adenosine”, “compound of formula (I)” and “first active ingredient” can be used interchangeably.
[0009] The term "second active ingredient" as used herein refers to a statin and / or a fibrate.
[0010] The term "statin" as used herein is a class of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, which are mainly used to reduce the production of cholesterol. Statins include, but are not limited to, atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin, cerivastatin, or pharmaceutically acceptable salts thereof. In some embodiments, the statin is simvastatin or a pharmaceutically acceptable salt thereof. In some embodiments, the statin is simvastatin.
[0011] The term "fibrate" as used herein is a class of benzoic acid derivatives that activate peroxisome proliferator-activated receptor α (PPARα), and its main function is to reduce triglyceride levels. Fibrates include but are not limited to binifibrate, bezafibrate, ciprofibrate, cholinefenofibrate, clinofibrate, clofibrate, fenofibrate, gemfibrozil, pemafibrate, ronifibrate, simfibrate, or their pharmaceutically acceptable salts. In some embodiments, the fibrate is fenofibrate or a pharmaceutically acceptable salt thereof. In some embodiments, the fibrate is fenofibrate.
[0012] The term "active ingredient" refers to molecules and agents of biologically, physiologically or pharmaceutically active substances that act in patients or subjects to prevent and / or treat diseases or conditions (e.g., hyperlipidemia or conditions associated with hyperlipidemia). The term is used relative to terms such as "pharmaceutically acceptable carriers", "excipients", "adjuvants", etc.
[0013] The term "pharmaceutically acceptable salt" as used herein, i.e., a pharmaceutically acceptable salt, refers to a pharmaceutically acceptable salt having the desired pharmacological activity of the parent compound. Pharmaceutically acceptable salts used herein are salts formed with pharmaceutically acceptable acids or bases. Pharmaceutically acceptable acids include, but are not limited to, inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, pyrophosphoric acid, hydrobromic acid or nitric acid, and organic acids such as citric acid, fumaric acid, maleic acid, malic acid, ascorbic acid, succinic acid, tartaric acid, benzoic acid, acetic acid, methanesulfonic acid, ethanesulfonic acid, salicylic acid, stearic acid, benzenesulfonic acid or p-toluenesulfonic acid. Pharmaceutically acceptable bases include hydroxides of alkali metals (e.g., sodium or potassium) and alkaline earth metals (e.g., calcium or magnesium), and organic bases such as alkylamines, arylamines or heterocyclic amines. For the avoidance of doubt, a "pharmaceutically acceptable salt" of an active ingredient described in the present application also includes a pharmaceutically acceptable salt formed by an isotope-labeled compound of the active ingredient, or its optical isomers, geometric isomers, tautomers or isomer mixtures, or a prodrug thereof.
[0014] It should be understood that all references to various active ingredients or pharmaceutically acceptable salts include solvent addition forms (solvates, such as hydrates, ethanol solvates, acetone solvates, etc.) or various crystal forms thereof (e.g., amorphous, polymorphs, etc.) of the same active ingredient or salt.
[0015] The pharmaceutical composition described herein may contain only the specified active ingredients, and may also contain one or more pharmaceutically acceptable solid or liquid carriers, excipients and / or adjuvants.
[0016] The kit described herein may include two independent preparation units, wherein the first preparation unit includes a therapeutically effective amount of a compound of formula (I) and optionally one or more pharmaceutically acceptable solid or liquid carriers, excipients and / or adjuvants, etc.; the second preparation unit includes a therapeutically effective amount of a statin or a fibrate and optionally one or more pharmaceutically acceptable solid or liquid carriers, excipients and / or adjuvants, etc. The kit may also include a container for containing separate preparation units, such as a separated bottle or a separated foil package, but the first preparation unit and the second preparation unit may also be contained in the same undivided container. The kit may also include instructions for use for guiding medication. The term "preparation unit" as used herein refers to a unit dosage form of a pharmaceutical preparation, which may be a drug or pharmaceutical composition containing a compound of formula (I) but not containing a statin or a fibrate, or a drug or pharmaceutical composition containing a statin or a fibrate but not containing a compound of formula (I).
[0017] The dosage form of the preparation unit in the pharmaceutical composition or medicine box of the present application can be a liquid dosage form, a solid dosage form or a semisolid dosage form. The liquid dosage form can be a solution (including a true solution and a colloidal solution), an emulsion (including an o / w type, a w / o type and a multiple emulsion), a suspension, an injection (including a water injection, a powder injection and an infusion), an eye drop, a nasal drop, a lotion and an liniment, etc.; the solid dosage form can be a tablet (including a common tablet, an enteric-coated tablet, a lozenge, a dispersible tablet, a chewable tablet, an effervescent tablet, an orally disintegrating tablet), a capsule (including a hard capsule, a soft capsule, an enteric-coated capsule), a granule, a powder, a pill, a suppository, a film, a patch, an aerosol (powder) aerosol, a spray, etc.; the semisolid dosage form can be an ointment, a gel, a paste, etc.
[0018] In some embodiments, the dosage form of the preparation unit in the pharmaceutical composition or medicine kit of the present application is tablet, capsule, pill and injection.
[0019] The pharmaceutical composition or the preparation unit in the medicine kit of the present application can be made into a common preparation, a sustained-release preparation, a controlled-release preparation, a targeted preparation and various microparticle drug delivery systems.
[0020] In order to prepare the pharmaceutical composition of the present application or the preparation unit in the medicine kit into tablets, various excipients known in the art can be widely used, including diluents, binders, wetting agents, disintegrants, lubricants, and glidants. The diluent may be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; the wetting agent may be water, ethanol, isopropanol, etc.; the binder may be starch slurry, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, acacia slurry, gelatin slurry, sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinyl pyrrolidone, polyethylene glycol, etc.; the disintegrant may be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitan fatty acid ester, sodium dodecyl sulfate, etc.; the lubricant and glidant may be talc, silicon dioxide, stearate, tartaric acid, liquid paraffin, polyethylene glycol, etc.
[0021] The tablets can be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets.
[0022] In order to prepare the pharmaceutical composition or the preparation unit in the medicine box of the present application into capsules, the active ingredient can be mixed with a diluent and a glidant, and the mixture can be directly placed in a hard capsule or a soft capsule. The active ingredient can also be first prepared into granules or pellets with a diluent, a binder, and a disintegrant, and then placed in a hard capsule or a soft capsule. The diluents, binders, wetting agents, disintegrants, and glidants used to prepare tablets can also be used to prepare capsules.
[0023] In order to prepare the pharmaceutical composition or the preparation unit in the kit of the present application into an injection, water, ethanol, isopropanol, propylene glycol or a mixture thereof can be used as a solvent and an appropriate amount of a solubilizer, a cosolvent, a pH adjuster, and an osmotic pressure regulator commonly used in the art can be added. The solubilizer or cosolvent can be poloxamer, lecithin, hydroxypropyl-β-cyclodextrin, etc.; the pH adjuster can be phosphate, acetate, hydrochloric acid, sodium hydroxide, etc.; the osmotic pressure regulator can be sodium chloride, mannitol, glucose, phosphate, acetate, etc. If a lyophilized powder injection is prepared, mannitol, glucose, etc. can also be added as a support agent.
[0024] Furthermore, if necessary, colorants, preservatives, perfumes, flavoring agents or other additives may be added to the pharmaceutical preparations.
[0025] The content of the active ingredient of the present application in its pharmaceutical composition or preparation unit can be adjusted according to actual needs (such as dosage form, administration method, administration object, etc.), for example, 0.1-95% by weight, such as 1-95% by weight, 1-90% by weight, etc.
[0026] The ratio of active ingredients in the pharmaceutical composition of the present application can be adjusted according to actual needs (e.g., dosage form, administration method, administration object, etc.). For example, in some embodiments, the ratio of the compound of formula (I) as the first active ingredient to the statin or fibrate as the second active ingredient can be 100:1 to 1:100, such as 100:1 to 1:50, 100:1 to 1:20, 100:1 to 1:10, 100:1 to 1:1, 100:1 to 2:1, 100:1 to 4:1, 50:1 to 1:1, 50:1 to 2:1, 50:1 to 4:1, 40:1 to 1:1, 40:1 to 2:1, 40:1 to 4:1.
[0027] Another aspect of the present application relates to the use of the above-mentioned compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with a statin or a fibrate in the preparation of a pharmaceutical composition or a kit for preventing and / or treating hyperlipidemia or a condition associated with hyperlipidemia.
[0028] The term "treatment" as used herein refers to the management or care of a subject in order to combat a disease, disorder or condition, including but not limited to preventing the occurrence of symptoms or complications, alleviating the disease, disorder, symptom or complication, arresting or slowing the progression of the disease, disorder, symptom or complication, or eliminating the disease, disorder, symptom or complication.
[0029] As used herein, the term "hyperlipidemia" refers to an abnormal increase in the level of lipids in the blood. Hyperlipidemia can occur in three forms: (1) hypercholesterolemia, which is an increase in cholesterol levels; (2) hypertriglyceridemia, which is an increase in triglyceride levels; and (3) combined hyperlipidemia, which is a combination of hypercholesterolemia and hypertriglyceridemia. "Hyperlipidemia" also refers to an increase in the level of one or more lipoproteins, such as lipoprotein a (Lp(a)), low-density lipoprotein (LDL) and / or very low-density lipoprotein (VLDL).
[0030] In some embodiments, the prevention and / or treatment of hyperlipidemia or a condition associated with hyperlipidemia comprises treating and / or preventing hypercholesterolemia, hypertriglyceridemia or combined hyperlipidemia. In some embodiments, the prevention and / or treatment of hyperlipidemia or a condition associated with hyperlipidemia comprises inhibiting the increase in the level of lipoprotein a (Lp(a)), low-density lipoprotein (LDL) and / or very low-density lipoprotein (VLDL), or reducing the level of lipoprotein a (Lp(a)), low-density lipoprotein (LDL) and / or very low-density lipoprotein (VLDL).
[0031] In some embodiments, the prevention and / or treatment of hyperlipidemia or a condition associated with hyperlipidemia comprises inhibiting the increase in the level of low-density lipoprotein cholesterol (LDL-C), total cholesterol (CHO), triglycerides (TG), or reducing the levels of LDL-C, CHO, TG.
[0032] Hyperlipidemia can be further divided into primary or secondary hyperlipidemia. Primary hyperlipidemia is usually caused by genetic defects, while secondary hyperlipidemia is usually caused by other factors such as various disease states, medications, and dietary factors. Alternatively, hyperlipidemia can be caused by a combination of primary and secondary causes of hyperlipidemia.
[0033] Exemplary primary hyperlipidemias include, but are not limited to, familial hyperchylomicronemia, familial hypercholesterolemia, familial combined hyperlipidemia, familial apolipoprotein B100 deficiency, familial dysbetalipoproteinemia (also known as type III hyperlipoproteinemia), and familial hypertriglyceridemia.
[0034] In some embodiments, the prevention and / or treatment of hyperlipidemia or a condition associated with hyperlipidemia comprises the prevention and / or treatment of familial hyperchylomicronemia, familial hypercholesterolemia, familial combined hyperlipidemia, familial apolipoprotein B100 deficiency, familial dysbetalipoproteinemia (also known as type III hyperlipoproteinemia), or familial hypertriglyceridemia.
[0035] Exemplary risk factors for secondary hyperlipidemia include, but are not limited to: (1) disease risk factors, such as type I diabetes, type II diabetes, Cushing's syndrome, hypothyroidism, cholestasis, and a history of some types of renal failure; (2) drug risk factors, which include birth control pills, hormones such as estrogens and corticosteroids, some diuretics, and various beta-blockers; (3) dietary risk factors, including cholesterol intake greater than 300 mg / day, habitual and excessive alcohol use, bulimia, anorexia nervosa, and obesity, etc.
[0036] In some embodiments, preventing and / or treating hyperlipidemia or a condition associated with hyperlipidemia comprises preventing and / or treating hyperlipidemia or a condition associated with hyperlipidemia caused by type I diabetes, type II diabetes, Cushing's syndrome, hypothyroidism, cholestasis, renal failure, birth control pills, hormones (such as estrogen and corticosteroids), diuretics, beta-blockers, excess cholesterol intake, habitual and excessive alcohol use, bulimia, anorexia nervosa, or obesity.
[0037] The conditions associated with hyperlipidemia described herein include, but are not limited to, coronary heart disease, atherosclerosis, angina pectoris, carotid artery disease, cerebral arteriosclerosis, xanthomas, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, myocardial infarction, dyslipidemia, and postprandial lipidemia.
[0038] Another aspect of the present application relates to a method for preventing and / or treating hyperlipidemia or a condition associated with hyperlipidemia, the method comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of the above-mentioned formula (I) or a pharmaceutically acceptable salt thereof as a first active ingredient, and a therapeutically effective amount of a statin or a fibrate as a second active ingredient.
[0039] The therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof as the first active ingredient and the therapeutically effective amount of a statin or a fibrate as the second active ingredient may be contained in the pharmaceutical composition or kit described above.
[0040] The term "therapeutically effective amount" refers to that amount of a drug that will elicit the biological or medical response of a tissue, system or animal (mammal) that is being sought by the researcher or clinician.
[0041] The terms "mammal", "subject" or "patient" are used interchangeably herein and include, but are not limited to, humans, dogs, cats, horses, pigs, cows, monkeys, rabbits, mice, and laboratory animals. Preferred mammals are humans.
[0042] The administration route of the first active ingredient, the second active ingredient, or the pharmaceutical composition or formulation unit containing the same can be enteral or parenteral, such as oral, intravenous, intramuscular, subcutaneous, nasal, oral mucosa, eyes, lungs and respiratory tract, skin, vagina, rectum, etc. In some preferred embodiments, the administration route is oral.
[0043] The first active ingredient and the second active ingredient may be administered simultaneously, or may be administered sequentially in any order or with a certain time interval (e.g. 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24 hours).
[0044] The frequency of administration of the first active ingredient, the second active ingredient, or a pharmaceutical composition or formulation unit comprising the same can be determined by a technician in the relevant field, for example, once a day, once every two days, once every three days, once every four days, once every five days, once every six days, twice a day, three times a day, etc.
[0045] The first active ingredient and the second active ingredient of the present application (or a pharmaceutical composition or preparation unit comprising the same) may be administered continuously for a period of 1 week, 2 weeks, 3 weeks or 4 weeks.
[0046] The dosage of the first active ingredient and the second active ingredient (or the pharmaceutical composition or preparation unit containing the same) of the present application can be determined by the clinician according to the actual situation (such as the patient's medical history, body weight, severity of the disease, etc.). For example, the daily dose of the first active ingredient of the present application can be 0.001-150 mg / kg body weight, 0.1-100 mg / kg body weight, 1-60 mg / kg body weight, 2-30 mg / kg body weight; the daily dose of the second active ingredient can be 0.0001-30 mg / kg body weight, such as 0.001-20 mg / kg body weight, 0.01-15 mg / kg body weight, 0.01-10 mg / kg body weight, 0.01-5 mg / kg body weight, 0.01-1 mg / kg body weight, 0.1-1 mg / kg body weight.
[0047] Beneficial technical effects: The applicant unexpectedly found that the combination of the compound of formula (I) and a statin or a fibrate showed a beneficial synergistic effect in the treatment of hyperlipidemia or a condition associated with hyperlipidemia, compared with a single treatment using only one of the active ingredients in the combination disclosed herein. Moreover, this synergy can produce additional benefits in the treatment, such as prolonged efficacy, better continuation of the therapeutic effect after drug withdrawal, fewer side effects, treatment of more symptoms or complications, reduced dosage, reduced frequency of administration, improved patient compliance, and the like.
[0048] Those skilled in the art will appreciate that the definitions and preferences described in one aspect of the present application are equally applicable to other aspects. Those skilled in the art will appreciate that the embodiments of various aspects of the present application can be combined in various ways without departing from the subject matter and ideas of the present application, and these combinations are also included in the scope of the present application. DETAILED DESCRIPTION
[0049] Example 1: Effect of combined drug therapy in golden hamster hyperlipidemia model
[0050] 1. Purpose of the experiment
[0051] The hyperlipidemia golden hamster model was used to observe the effect of the test substance 2',3',5'-tri-O-acetyl-N 6 The lipid-lowering pharmacodynamic synergistic effect of -(3-hydroxyphenyl)adenosine (hereinafter referred to as "IMM-H007") (200 mg / kg) combined with simvastatin (6 mg / kg) or fenofibrate (50 mg / kg).
[0052] 2. Experimental Materials
[0053] Experimental animals: Golden hamsters, male, 8-9 weeks old, provided by Beijing Weitonglihua Laboratory Animal Technology Co., Ltd., license number: SCXK (Beijing) 2012-0001; No.11400700190131
[0054] Test product: IMM-H007, batch number: 20140601, purity: 99.8%, prepared with 0.5% sodium carboxymethyl cellulose (CMC-Na) to the required concentration before use.
[0055] Kits: Total cholesterol kit (CHO), triglyceride kit (TG), low-density lipoprotein cholesterol kit (LDL-C), glucose kit (Glu), Biopharmaceuticals Co., Ltd.
[0056] Instrument: Toshiba 40 fully automatic biochemical analyzer
[0057] Feed: High-fat feed formula: 79.8% basic feed, 20% lard, 0.2% cholesterol, provided by Beijing Huafukang Biotechnology Co., Ltd., license number: SCXK (Beijing) 2014-0008
[0058] 3. Experimental Methods
[0059] Animal model preparation: The animals were purchased and adaptively fed for one week. Except for the normal control group (10 animals), the remaining animals were fed with a high-fat diet for one week and then given the drug.
[0060] Grouping and administration: According to body weight, the animals were randomly divided into model control group, positive control drug simvastatin (6 mg / kg), positive control drug fenofibrate (50 mg / kg), IMM-H007 (200 mg / kg), combined administration 1 (simvastatin 6 mg / kg and IMM-H007 200 mg / kg), combined administration 2 (fenofibrate 50 mg / kg and IMM-H007 200 mg / kg), 10 animals in each group. The animals were given oral administration once a day, with a volume of 1 ml / 100 g. The normal control group and model control group were given an equal volume of solvent (0.5% CMC·Na) for two consecutive weeks. The drug was stopped for one week, and the recovery of various serum indicators of the animals was observed.
[0061] Blood lipid test: Blood was collected 2 weeks after administration and 1 week after drug withdrawal to measure serum low-density lipoprotein cholesterol (LDL-C), total cholesterol (CHO), triglyceride (TG) and glucose (Glu) levels.
[0062] Data analysis: IBM SPSS Statistics 26 software was used for statistical analysis. Continuous variables were first tested for normality using the Shapiro-Wilk test. If the P value > 0.05, it indicated that the variable was in accordance with the normal distribution and was expressed as mean ± standard deviation; if it was not in accordance with the normal distribution, it was expressed as median (interquartile range). Levene's test was used for variance homogeneity test. If the P value > 0.05, it indicated that the variance between the data was homogeneous. If all groups met the normality and the variance between the groups was homogeneous, the independent sample T test was used for comparison between the two groups or the one-way ANOVA test LSD method was used for comparison between multiple groups; if the groups met the normality but the variance was not homogeneous, the approximate T test was used for comparison between the two groups; if the groups did not meet the normal distribution, the nonparametric Mann-Whitney U test was used for comparison between two independent samples or the Kruskal-Wallis H test was used for comparison between multiple groups. P < 0.05 was considered statistically significant. All tests were two-sided.
[0063] 4. Experimental Results
[0064] After two weeks of administration, compared with the normal control group, the serum LDL-C, CHO, TG, and Glu of the animals in the model control group were significantly increased (P<0.05). Compared with the model control group, the TG of the animals in the positive control drug simvastatin (6 mg / kg) group was significantly reduced (P<0.05); the LDL-C, TC, and TG of the positive control drug fenofibrate (50 mg / kg) group were significantly reduced (P<0.05); the LDL-C, TC, and TG of the IMM-H007 (200 mg / kg) group were significantly reduced (P<0.05) (see Table 1).
[0065] Compared with the positive control drug simvastatin (6 mg / kg) group, LDL-C, TC, TG, and Glu in the combined administration 1 (simvastatin 6 mg / kg and IMM-H007 200 mg / kg) group were all reduced, with extremely significant statistical differences (P<0.01). Compared with the positive control drug fenofibrate (50 mg / kg) group, TG in the combined administration 2 (fenofibrate 50 mg / kg and IMM-H007 200 mg / kg) group was significantly reduced, with extremely significant statistical differences (P<0.01) (see Table 2).
[0066] One week after drug withdrawal, compared with the model control group, the serum TG of animals in the combined drug 1 (simvastatin 6 mg / kg and IMM-H007 200 mg / kg) group and the combined drug 2 (fenofibrate 50 mg / kg and IMM-H007 200 mg / kg) group was still significantly decreased (P<0.05); the serum TC of animals in the positive control drug fenofibrate (50 mg / kg) group was still lower than that of the model group (P<0.05); the serum TG of animals in the positive control drug simvastatin (6 mg / kg) group was still lower than that of the model group (P<0.01). All serum indicators of animals in other drug groups returned to the level of the model control group (see Table 3).
[0067] Table 1 Serum lipid results (mmol / L) of golden hamsters treated with IMM-H007 combined with simvastatin or fenofibrate for two weeks
[0068]
[0069]
[0070] Compared with the normal group, # P<0.05, ## P<0.01; compared with the model group, * P<0.05, ** P < 0.01. Normally distributed data are expressed as mean ± standard deviation, and non-normally distributed data are expressed as median (interquartile range).
[0071] Table 2 Serum lipid results (mmol / L) of golden hamsters treated with IMM-H007 combined with simvastatin or fenofibrate alone for two weeks
[0072]
[0073] Compared with the simvastatin group, * P<0.05, ** P<0.01; compared with the fenofibrate group, # P<0.05, ##P < 0.01. Normally distributed data are expressed as mean ± standard deviation, and non-normally distributed data are expressed as median (interquartile range).
[0074] Table 3 Serum lipid results (mmol / L) of golden hamsters after combined drug withdrawal for one week
[0075]
[0076]
[0077] Compared with the normal group, # P<0.05, ## P<0.01; compared with the model group, * P<0.05, ** P < 0.01. Normally distributed data are expressed as mean ± standard deviation, and non-normally distributed data are expressed as median (interquartile range).
[0078] 5. Experimental Conclusion
[0079] IMM-H007 was administered in combination with simvastatin and fenofibrate for two weeks, which had a synergistic effect on improving lipid metabolism disorders in hyperlipidemic golden hamsters. After one week of drug withdrawal, except for the TG index, all other indicators in the combined administration group returned to the level of the model control group.
Claims
1. A pharmaceutical composition, characterized in that The composition comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof and simvastatin, or a compound of formula (I) or a pharmaceutically acceptable salt thereof and fenofibrate, wherein the weight ratio of the compound of formula (I) to simvastatin or fenofibrate is 100:1 to 1:100, 2. The pharmaceutical composition according to claim 1, wherein the dosage form of the pharmaceutical composition is selected from tablets, capsules, pills or injections.
3. Use of a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof and simvastatin or fenofibrate in the preparation of a medicament or a kit for preventing and / or treating hyperlipidemia or lipid metabolism disorders, wherein the weight ratio of the compound of formula (I) to simvastatin or fenofibrate is 100:1 to 1:100,
